Pfizer has entered into a Delegation of Authority with AstraZeneca Pharma India (AstraZeneca), pursuant to which AstraZeneca has granted certain authority to the company to conduct certain activities in India (DoA). The said Delegation of Authority is a result of a global agreement whereby Pfizer Inc. through its affiliates acquired from AstraZeneca PLC (through its affiliates) the development and commercial rights of their late-stage small molecule anti-infectives business.
By way of this DoA, the company has been granted the authority, to carry out the activities of pricing and reimbursement negotiations, promotional, marketing, tendering, bidding, and distribution in relation to the identified injectable antibiotic products. Pursuant to this, Meronem IV Injection which is currently marketed in India by AstraZeneca is expected to be transitioned to the company.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.
